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We identify matrix metalloproteinase (MMP)-8, the polymorphonuclear (PMN) leukocyte collagenase, as a critical mediator
initiating lipopolysaccharide (LPS)-responsiveness in vivo. PMN infiltration towards LPS is abrogated in Mmp8-null mice. MMP-
8 cleaves LPS-induced CXC chemokine (LIX) at Ser
4,Val
5 and Lys
79,Arg
80. LIX bioactivity is increased upon N-terminal
cleavage, enhancing intracellular calcium mobilization and chemotaxis upon binding its cognate receptor, CXCR2. As there is
no difference in PMN chemotaxis in Mmp8-null mice compared with wild-type mice towards synthetic analogues of MMP-8-
cleaved LIX, MMP-8 is not essential for extravasation or cell migration in collagenous matrices in vivo. However, with
biochemical redundancy between MMPs 1, 2, 9, and 13, which also cleave LIX at position 4,5, it was surprising to observe such
a markedly reduced PMN infiltration towards LPS and LIX in Mmp8-/- mice. This lack of physiological redundancy in vivo
identifies MMP-8 as a key mediator in the regulation of innate immunity. Comparable results were found with CXCL8/IL-8 and
CXCL5/ENA-78, the human orthologues of LIX. MMP-8 cleaves CXCL8 at Arg
5-Ser
6 and at Val
7-Leu
8 in CXCL5 to activate
respective chemokines. Hence, rather than collagen, these PMN chemoattractants are important MMP-8 substrates in vivo;
PMN-derived MMP-8 cleaves and activates LIX to execute an in cis PMN-controlled feed-forward mechanism to orchestrate the
initial inflammatory response and promote LPS responsiveness in tissue.
Citation: Tester AM, Cox JH, Connor AR, Starr AE, Dean RA, et al (2007) LPS Responsiveness and Neutrophil Chemotaxis In Vivo Require PMN MMP-8
Activity. PLoS ONE 2(3): e312. doi:10.1371/journal.pone.0000312
INTRODUCTION
Polymorphonuclear neutrophils (PMNs) are crucial inflammatory
leukocytes in host protection from infection, where their primary
role is in phagocytosis and killing of bacteria, fungi and protozoa,
and in wound debridement and healing [1,2]. Given these critical
roles of PMNs, it has long been recognised that neutropenic
patients are at greater risk of infection [3], and that is often
observed after intensive cancer chemotherapy [4,5]. Proteolysis of
phagosome contents and damaged extracellular matrix are key
PMN actions in inflammation. Cell migration, crossing basement
membrane and connective tissue matrix barriers are other aspects
of PMN function traditionally thought to require proteolytic
activity [6]. Additionally, PMNs are a source of chemotactic
factors that guide the recruitment of specific and non-specific
immune effector cells [7] and so these first line defence cells play
key roles in innate and acquired immunity.
Of the two major chemokine subfamilies that provide di-
rectional cues for leukocyte migration and activation [8], the CXC
chemokines predominantly influence PMNs and T-lymphocytes
whereas the CC chemokines are active on monocytes, basophils
and eosinophils [9]. The expression of CXC chemokines is rapidly
upregulated during acute inflammatory responses, such as that
initiated by the endotoxin lipopolysaccaride (LPS) [10–13]. A
subset of the CXC chemokines are characterised by an ELR
(glutamic acid-leucine-arginine) sequence proximal to the con-
served CXC motif. ELR is essential for binding CXC-receptors
(CXCR) 1 and 2 [14] leading to PMN activation, degranulation
and release of proteases [15]. The murine ELR
+ CXC chemokines
act through a single receptor that is homologous to human
CXCR2 [16]. In humans there are seven ELR
+ CXC chemokines;
CXCL8/interleukin-8 (IL-8); CXCL7/neutrophil-activating pep-
tide-2 (NAP-2); CXCL6/granulocyte chemotactic protein-2
(GCP-2); CXCL5/epithelial cell-derived neutrophil activating
peptide-78 (ENA-78); and CXCL1, -2 and -3 (also known as
growth-related oncogenes (GRO) a,- b, and -c). Only CXCL8/IL-
8, the most potent of these chemokines, and CXCL6/GCP-2 bind
CXCR1, whereas all members signal through the closely related
receptor CXCR2 [14]. Mice lack a homologue of CXCL8/IL-8
having only four ELR
+ CXC chemokines: LPS-induced CXC
chemokine (LIX), the most abundant and potent of the murine
chemokines and regarded as the orthologue of CXCL8 [17];
keratinocyte-derived chemokine (KC); macrophage inflammatory
protein-2 (MIP-2); and dendritic cell inflammatory protein-1
(DCIP-1). Physiological N-terminal cleavage of chemokines
modifies their bioactivity—either enhancing activity of the ELR
+
CXC chemokines [15] or generating potent receptor antagonists
from the CC chemokines CCL2, -7, -8 and -13 (also known as
macrophage chemotactic proteins 1 to 4) [18,19]. Although several
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Matrix metalloproteinases (MMPs) are traditionally associated
with extracellular matrix protein degradation in many physiolog-
ical and pathological processes, including inflammation, bacterial
infection, wound healing, and cancer cell invasiveness (reviewed in
ref [20]). However, it is now clear that MMPs mediate homeostasis
of the extracellular environment [21] by modulating the biological
activity of many bioactive molecules involved in cell function
[22,23], innate immunity [24] including chemokines [18,19,23,
25–27], TNF-a [22,28], a-defensin [29], and mannose binding
lectin [30], and in tumour initiation and progression. Inflamma-
tion in cancer, particularly macrophage infiltration and MMP-9
release, generates a microenvironment advantageous to neoplastic
progression [31], with recent evidence indicating that a PMN
source of MMP-9 can also promote tumorigenesis [32].
MMP-8 (human: P22894, mouse: CAA73786, rat: AJ007288),
the neutrophil collagenase, is produced primarily by PMNs and is
released from the specific granules at sites of inflammation [33].
Mmp8-null mice have no overt phenotype, with normal embryonic
development, fertility, and long-term survival [34]. In contrast to
other MMP deficient mice [35], Mmp8-null mice challenged with
carcinogens showed a markedly increased susceptibility to
tumorigenesis [34], but this only occurred in male mice. This
was the first report of a MMP having a protective role in
tumorigenesis, so validating MMP-8 as an anti-target in cancer
therapy [35].
As a potent type I collagenase [36,37] it had been predicted that
mice lacking the Mmp8 gene would show reduced PMN migration
through collagenous matrices [34]. Indeed, at the tumor stromal
interface an abnormal inflammatory response is observed,
characterised by an initially delayed and then a more diffuse
PMN influx in the Mmp8-null mice [34]. However, once
established there was a prolonged chronic accumulation of PMNs
that did not dissipate. Overall, this phenotype is reversed following
transplantation of wild type bone marrow, confirming that the
absence of MMP-8 produced by PMNs and not a tissue or tumour
source resulted in the higher incidence of tumors. In a model of
TNF-induced acute hepatitis, MMP-8 deficient mice showed
dampened levels of PMN infiltration into the liver that was
postulated to result from reduced LIX mobilization from an
unidentified binding protein in the matrix [38]. Together, these
studies suggest a coordinating role for MMP-8 in physiological
leukocyte trafficking both in acute and chronic inflammation,
either through cleavage of collagen or chemokine binding proteins
[38], or by processing of bioactive molecules, such as LIX [34] to
control PMN migration or longevity.
Here we have investigated the role of MMP-8 in PMN
recruitment during acute inflammation using LPS responsiveness
as a trigger; the PMN influx was abrogated in the Mmp8-/- mouse.
LIX is identified as a key inflammatory substrate of MMP-8 where
N-terminal processing by MMP-8 activates the chemokine and so
increases PMN chemotaxis and LPS responsiveness in vitro and in
vivo. Although these activities are reduced in the Mmp8-null mouse,
the loss of neutrophil collagenolytic activity did not alter in vitro
PMN chemokinesis or in vivo chemotaxis when challenged with
truncated LIX or truncated CXCL8/IL-8 chemokines. Hence,
these data reveal a new auto-regulatory mechanism of PMN
chemotaxis that is initiated by MMP-8 release from PMNs and
executed, directly or indirectly, by the proteolytic activation of
LIX in mice and CXCL8 and CXCL5/ENA-78 in man. This
drives further PMN migration in a novel feed-forward mechanism
that, remarkably, is a major determinant of LPS responsiveness.
RESULTS
LPS induced PMN response in mice
To ascertain the role of MMP-8 in PMN cell migration and LPS
responsiveness in vivo we compared Mmp8-/- with Mmp8+/+ mice.
The PMN influx was significantly reduced (P#0.005) when LPS
was injected in air pouches formed under the dorsal skin of the
MMP-8 knockout mice compared with wild type mice (Figure 1A).
This was observed in both male and female mice, although the
PMN infiltrate was generally greater in the females towards both
LPS and the PBS control. Hence, the reduced PMN migration
and accumulation in Mmp8-/- mice reveals a critical role for this
PMN-specific protease in neutrophil function in acute inflamma-
tion. Notably, MMP-8 was only detected in cell lysates from LPS-
treated air pouches of wild type mice, revealing both the pro and
active forms of the enzyme at 85 and 65 kDa, respectively
(Figure 1B). A 30-kDa inactive degradation product of MMP-8
was also detected, as observed previously [39].
MMP-8 processing of murine ELR
+ CXC chemokines
We investigated the potential role of MMP-8 to modulate the
activity of the cognate ELR
+ ligands of CXCR2 that may underlie
the defect in LPS-induced PMN migration. The four murine
ELR
+ CXC chemokines LIX, KC, MIP-2, and DCIP-1 were
Figure 1. Impaired PMN responsiveness to LPS in MMP-8 deficient mice. (A) Infiltration of PMNs in vivo in response 1 mg of LPS (n=8) or phosphate
buffered saline control (n=4) injected into the air pouch of male Mmp8-/- (black bar) and wild type mice (white bar) was assessed 8 h post-injection.
The PMN influx was quantitated by myeloperoxidase activity. Error bars, standard error. (B) Western blot analysis of murine MMP-8 in LPS-treated air
pouch PMN lysates corresponding to 50,000 cells per lane.
doi:10.1371/journal.pone.0000312.g001
LIX Processing by MMP-8
PLoS ONE | www.plosone.org 2 March 2007 | Issue 3 | e312incubated with recombinant MMP-8. Of these, LIX was the only
chemokine susceptible to proteolytic processing (Figure 2A)—KC,
MIP-2, and DCIP-1 were MMP-8-resistant even at high
enzyme:substrate ratios (1:10) and after prolonged incubation
times revealing protease substrate specificity. MALDI-TOF mass
spectrometry analysis of the LIX cleavage products showed that
MMP-8 processed the chemokine at two sites. The major product
of 9,511 Da represents a deletion of the first four NH2-terminal
amino acid residues. Edman sequencing confirmed the deconvo-
luted MALDI-TOF data (Figure 2B). Hence, MMP-8 cleaves the
92-amino acid residue LIX between Ser,Val at position 4-5 to
generate a new NH2-terminus at Val
5 that we designate LIX (5-
92). With a measured mass of 8,113 Da, the second cleavage
product was processed near the COOH-terminus after Lys
79,
resulting in the removal of 13 amino acid residues and generating
the truncated form of LIX designated LIX (5-79) (Figure 2B). LIX
(1-79) was never detected. Edman sequencing confirmed the
deconvoluted mass spectrometry analysis of the Ser
4,Val
5 amino-
terminal cleavage site of LIX (5-79).
As determined by MALDI-TOF mass spectrometry, the NH2-
and COOH-terminal processing of LIX was efficient; the cleavage
products were first detected by mass spectrometry after 1 h with
no full-length chemokine remaining at 18 h (Figure 2C). The
COOH-terminal cleavage product was not detected in the absence
of NH2-terminal processing at any time point indicating it occurs
subsequent to NH2-terminal cleavage. Although the C-terminal
cleavage was at an unusual highly cationic site
75KKKAK,R-
NALA
84 it was confirmed to be MMP dependent as two MMP
Figure 2. MMP-8 Cleavage of LIX. (A) Tris-tricine 15% SDS-PAGE gel analysis of MMP-8 cleavage of murine CXCR2-binding chemokines DCIP-1, KC,
LIX and MIP-2. The m/z [M+H]
+ of reaction products are as shown. (B) Identification of cleavage products by MALDI-TOF mass spectrometry and NH2-
terminal Edman sequencing. n.d., not determined. (C) Tris-tricine 15% SDS-PAGE and MALDI-TOF analysis of LIX cleavage products generated over
time (h) by MMP-8. (D) Tris-tricine 15% SDS-PAGE and MALDI-TOF analysis of LIX cleavage by MMP-8 in the presence of 10-fold molar excess of
recombinant hemopexin C-domain (MMP-8 CD), 10 mM EDTA, or 10 mM BB94. (E) Heparin Sepharose AKTA chromatograms of synthetic analogues of
MMP-8 cleavage products of LIX eluted with a linear gradient of NaCl as indicated.
doi:10.1371/journal.pone.0000312.g002
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chemical inhibitor BB94, blocked all LIX processing with no
cleavage products detected by MALDI-TOF mass spectrometry or
Tris-tricine SDS-PAGE (Figure 2D). Chemokine cleavage is often
enhanced by MMP exosite interactions [40]. For instance, the
hemopexin C domain of MMP-2 greatly increases the catalytic
rate constants of CCL2, -7, -8 and -13 cleavage [19]. When molar
excess of recombinant MMP-8 hemopexin C-domain was added
in the cleavage assays, we likewise found that all LIX processing by
MMP-8 was abrogated revealing that a binding site for LIX was
present on the hemopexin C domain of MMP-8 (Figure 2D). The
C-terminal cleavage at Lys
79,Arg
80 only slightly reduced heparin
affinity (Figure 2E) consistent with the removal of just two basic
residues in the cleaved peptide
80RNALAVERTASVQ
92 while
the N-terminal truncation had no effect on heparin binding.
Processing of LIX by other MMPs
Proteolytic screening of LIX cleavage by several MMPs showed
that MMP-9, a prominent PMN MMP, processed LIX at
Ser
4,Val
5 (Figure 3). In addition to MMP-9, other important
stromal, endothelial and leukocytic MMPs 1, -2, and -13 could
also process LIX at Ser
4,Val
5 (Figure 3), but like MMP-8, did not
cleave KC, MIP-2, or DCIP-1 (not shown). Similar redundancy
has been shown with MMPs for CXCL12 (also know as SDF-1)
[25] and for CCL2, -7, -8 and -13 [19]. Protease selectivity was
also shown with MMP-14, the RNA of which is also expressed by
PMNs (data not shown), but was incapable of processing LIX at
any position (Figure 3A). Further, only MMP-8 could process the
C-terminus of LIX at Lys
79,Arg
80.
Effect of LIX processing on in vitro biological activity
Upon binding to the receptor CXCR2, LIX mobilizes intracel-
lular Ca
++ ion stores. As measured in recombinant CXCR2-
expressing murine pre-B 300-19 cells, synthetic analogues of the
MMP-truncated forms of LIX (5-92) and LIX (5-79) both induced
an ,2-fold greater intracellular Ca
++ ion release compared to full-
length LIX (1-92) (Figure 4A). This was confirmed using murine
Mmp8-/- PMNs where an even greater stimulation in Ca
++ ion
release was observed upon binding LIX (5-92) compared with full-
length LIX (Figure 4B). Functionally, this translated into enhanced
chemoattraction for the CXCR2-expressing pre-B 300-19 cells by
both of the truncated forms of LIX versus the full-length
chemokine (Figure 4C), and in purified PMNs from Mmp8+/+
mice compared to the unprocessed LIX (1-92) (Figure 4D).
Notably, PMNs isolated from Mmp8-/- mice migrated towards
LIX (5-92) in a comparable manner to the Mmp8+/+ PMNs
(Figure 4D and data not shown) indicating that the locomotor
functions of PMNs isolated from both wild type and MMP-8
knock out mice were equivalent in vitro and unaffected by the
presence or absence of MMP-8.
In vivo PMN chemotaxis towards LIX
Infiltration of PMNs towards LIX (1-92) injected in a dorsal skin
air pouch of Mmp8-/- mice was impaired at all time points
compared to PMN infiltration in wild type mice, with an ,2-fold
lower number of PMNs seen at 8 and 12 h in knock out compared
with wild type mice (Figure 5). In contrast, when LIX (5-92) or
LIX (5-79) were used as chemoattractants there was no significant
difference in PMN infiltration into the air pouches of wild type and
mice lacking MMP-8 (Figure 5). This indicates that MMP-8
activity is not essential for blood vessel extravasation and PMN cell
migration in vivo and that there is little physiological redundancy
by PMN MMP-9, or from tissue MMPs that we found competent
in cleaving and activating LIX in the biochemical context in vitro.
MMP-8 processes and activates IL-8 and ENA-78
Our experimental data suggest that upon LPS-induced release of
LIX and resultant PMN chemoattraction a feed-forward PMN
activation mechanism operates in vivo. MMP-8 released from
degranulating PMNs at the site of challenge fully activates LIX in
the tissue to further enhance PMN migration towards the LPS
stimulus. To ascertain whether a similar autologous CXCR2
ligand activation mechanism occurs in man we assessed every
human CXCR2 ligand for MMP-8 cleavage. Of the seven ELR
+
CXC chemokines (CXCL8/IL-8, CXCL7/NAP-2, CXCL6/
GCP-2, CXCL5/ENA-78, CXCL3/GROc, CXCL2/GROb
and CXCL1/GROa) only CXCL8 and CXCL5 were processed
by MMP-8. By MALDI-TOF MS and confirmation by Edman
sequencing, CXCL8 was NH2-terminally processed by MMP-8 at
Arg
5,Ser
6 to generate CXCL8 (6-77) (Figure 6A, C) whereas
CXCL5 was cleaved at Val
7,Leu
8 to generate CXCL5 (8-78)
(Figure 6C). There were no COOH-terminal cleavages detected.
Another difference from the murine system was that CXCL8
cleavage was not hemopexin C domain dependent—proteolysis
was not inhibited in the presence of a molar excess of hemopexin
C domain (Figure 6B).
Figure 3. LIX is selectively cleaved by multiple MMPs. (A) Tris-tricine
SDS-PAGE and MALDI-TOF mass spectrometry analysis of MMP
processing of LIX (enzyme:substrate ratio of 1:100 (w:w)) showing that
MMPs 1, 2, 8, 9 and 13 cleave LIX at position 4–5, whereas MMP-14 does
not, and that only MMP-8 also cleaves at position 79,80. Cleavage
assays of rodent MMP-8 and MMP-13 are shown in the second 8 and 13
lanes. (B) Cleavage data are summarised using the full-length sequence
of LIX.
doi:10.1371/journal.pone.0000312.g003
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for cleavage of CXCL5 and CXCL8. Only MMP-1 and MMP-8
cleaved CXCL5, with MMPs 1, 8, 9, 13 and 14 cleaving CXCL8.
Some differences in cleavage site specificity were identified, but all
cleavages were NH2-terminal to the ELR motif (Figure 6D) and
none cut in the C-terminal a-helix, as occurs for LIX. Consistent
with previous studies [15,26,27] and our results with MMP-8
cleavage of LIX, MMP-8 processing of CXCL8 markedly
Figure 4. In vitro cellular responses to MMP-8 cleaved LIX. (A) Enhanced intracellular calcium mobilization was induced by LIX (5-92) and LIX (5-79)
compared to full-length LIX (1-92) in recombinant CXCR2-expressing B300-19 cells and (B) PMNs isolated from Mmp8-/- mice (100 nM chemokine). (C)
By transwell cell migration assay, both LIX (5-92) and LIX (5-79) truncated forms are more potent chemoattractants compared with the full-length LIX
(1-92) for both CXCR2-expressing B300-19 cell transfectants and (D) murine PMNs isolated from either Mmp8+/+ or Mmp8-/- mice, all at 10 nM
chemokine concentration.
doi:10.1371/journal.pone.0000312.g004
Figure 5. MMP-8 is required for PMN chemotaxis towards LIX in vivo, but is not required for PMN cell migration. PMN infiltration was greatly
reduced in response to full-length LIX (1-92) injected into the dorsal skin air pouch of Mmp8-/- mice (black bars) compared to wild type mice (white
bars). PMN numbers were calculated from myeloperoxidase assay after sacrifice at 0, 4, 8 and 12 h following injection of chemokine (n=4). Unaltered
PMN cell migration into air pouches of Mmp8-/- mice (black bars) compared to wild type mice (white bars) injected with MMP-cleaved analogues of
LIX (5-92 or 5-79) reveals no intrinsic cell kinesis defects or chemotactic ability in the PMNs of the knock out mice.
doi:10.1371/journal.pone.0000312.g005
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intracellular Ca
++ mobilization (Figure 7A) and commensurate cell
migration in transwells in vitro (Figure 7B). Despite several MMPs
biochemically characterised to cleave and activate CXCL8, the
critical importance of MMP-8 in CXCL8 activation was shown by
injecting full-length CXCL8 in the air pouches of Mmp8-/- mice
(Figure 7C). Here, the early PMN migration was decreased by
.50% at 4 h compared with wild type mice. At later time points,
there was less of a difference, but still it was always depressed in the
knock out mice. Mmp8-/- PMN responsiveness and cell migratory
behaviour in vivo was also shown to be unaffected by the absence of
MMP-8 when challenged with the synthetic analogue of MMP-8-
cleaved CXCL8 (6-77) (Figure 7C). This reconfirms the critical
role of MMP-8 in directing chemotaxis by chemokine processing
rather than cleavage of other molecules such as those in the blood
vessel wall or extracellular matrix. Similar results were obtained
using synthetic analogues of MMP-8-cleaved CXCL5 (8-78)
compared with full-length CXCL5 (1-78) in the air pouch model
(data not shown). In using human chemokines in a murine setting,
it was important to show that rodent MMP-8 did cleave CXCL8
at the same site as human MMP-8 (Figure 6A, D). However,
rodent MMP-8 cleaved human CXCL5 at Arg
9,Glu
10 with no
cleavage detected at Val
7,Leu
8 (Figure 6D). Hence, these in vitro
and in vivo studies indicate that similar to PMN migration
mechanisms towards LIX in mice, human PMN chemoattraction
in response to CXCL8 and CXCL5 also exhibits a unique MMP-8
dependent feed-forward activation mechanism.
DISCUSSION
We have addressed the role of MMPs in the activation of ELR
+
CXC chemokines in vivo. Using Mmp8-/- mice, the essential role of
PMN MMP-8 was shown in the activation pathway of the murine
CXC chemokine LIX and human CXCL5 and CXCL8.
Reflecting this, the absence of MMP-8 led to a profoundly
defective PMN infiltration response in vivo to LPS or to full-length
LIX, CXCL8, and CXCL5. This occurred despite the bio-
chemical redundancy in chemokine activation by several com-
monly expressed MMPs including 1, 2, 9, 13, and 14 in
a chemokine specific manner. PMN MMP-8 proteolysis leads to
the activation of selected ELR
+ CXC chemokines responsible for
directing PMN cell migration and activation in vivo. With MMP-8
being primarily expressed by PMNs, our study identifies MMP-8
as an essential mediator of an interesting and unique activation
mechanism of PMNs in innate immunity. This highlights an
unexpectedly important role of the PMN itself in the integration of
stimuli for the appropriate release of MMP-8 for LIX, CXCL8,
Figure 6. MMP processing of CXCL8 and CXCL5. (A) Tris-tricine 15% SDS-PAGE gel and MALDI-TOF mass spectrometry analysis of CXCL8 cleavage
products after assay with the indicated human MMPs at an enzyme to substrate ratio of 1:100. Cleavage assays of rodent MMP-8 are shown in the
second 8 lane. The NH2-terminus of the CXCL8 truncated forms were deconvoluted from the mass spectrometry data and confirmed by Edman
sequencing (as shown in C) with the CXCL8 forms identified shown below the corresponding gel lanes. 1-77, full-length CXCL8. (B) The effect of
recombinant MMP-8 hemopexin C domain (MMP-8 CD), 10 mM EDTA, or 10 mM BB94 on CXCL8 cleavage by human MMP-8 as determined by Tris-
tricine 15% SDS-PAGE and MALDI-TOF mass spectrometry. The m/z [M+H]
+ of reaction products is as shown. (C) Identification of the NH2-termini of
MMP cleavage products of CXCL8 and CXCL5 by MALDI-TOF mass spectrometry and NH2-terminal Edman sequencing. n.d., not determined. (D)
Location of the various MMP cleavage sites on the CXCL8 and CXCL5 sequences.
doi:10.1371/journal.pone.0000312.g006
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activation mechanism that acts in a feed-forward manner to
orchestrate the PMN influx and LPS responsiveness.
Precise control of innate immunity is key for the development of
successful inflammatory responses, resolution of infection, tissue
healing, and ultimately host survival. As first line defence cells, the
rapid recruitment and efficient activation of PMNs is of critical
importance. It has long been known that the ELR
+ CXCR2
cognate ligands that direct PMN chemotaxis and activation are
expressed as relatively inactive ligands requiring proteolytic
truncation of up to eight amino acid residues from the amino
terminus for full activity, providing that the essential ELR motif
remains intact [15]. However, relatively little attention has been
focused on identifying the responsible enzymes in vivo and the
location of chemokine activation—key questions for understanding
the control of PMN function and innate immunity mechanisms.
Naturally occurring NH2-terminal truncated forms of ELR
+ CXC
chemokines including LIX [17,41], CXCL8 [42], CXCL1, 3 and
5 [43], have been reported but the proteases involved have not
been identified in vivo. Mice deficient in MMP-9 [44], neutrophil
elastase [45], both MMP-9 and neutrophil elastase [46], or
cathepsin G [47] exhibit a normal PMN chemotactic response,
indicating that PMNs neither require these enzymes for CXC
chemokine activation, nor for migration and efficient chemotaxis
in vivo. Hence, the deficient LPS and PMN migratory responses in
the Mmp8-/- mouse are unique and reveal the singular importance
of MMP-8 in these processes. However, we do not discount the
possibility that in vivo other proteases downstream of MMP-8
activity may also activate LIX.
Consistent with previous observations [15,34,41] was our
demonstration through the use of in vitro calcium flux and
chemotaxis assays that the MMP-8-processed chemokine products
LIX (5-92), LIX (5-79), CXCL8 (6-77), and CXCL5 (8-78) were
more potent than the full-length chemokines. Notably, LIX (5-92)
and (5-79) were equally potent chemokines indicating that the C-
terminal cleavage at position Lys
79,Arg
80 did not influence
chemotactic activity. Chemokines interact with the highly
negatively charged glycosaminoglycan chains of proteoglycans
resulting in immobilization and the generation of a haptotactic
gradient within the extracellular matrix that is responsible for
directing leukocyte migration [48]. This has been confirmed
physiologically for CC type chemokines [49] and murine ELR
+
CXC chemokines [50]. Binding is typically through a heparin
binding consensus sequence BBXB where B is a basic residue [51].
The MMP-8 C-terminal cleavage of LIX only removes two basic
amino acids, both arginines, in the truncated product and so only
slightly reduces heparin affinity. The biological significance of this
cleavage is therefore unknown.
None of the MMPs analysed could cleave any of the other
murine ELR
+ chemokines (data not shown) revealing the
specificity of MMP chemokine cleavage. This susceptibility of
LIX to MMP processing is likely due to an extended N-terminus
before the ELR motif, as compared with KC, MIP-2, and DCIP-
1. Interestingly, rodent MMP-8 cleaved CXCL5 at Val
7,Leu
8
Figure 7. Enhanced bioactivity of MMP-truncated CXCL8 in vitro and in vivo. (A) Ca
++ ion mobilization with 10 nM CXCL8 and (B) chemotaxis of
CXCR2-transfected B300-19 cells stimulated with 10 nM full-length CXCL8 (1-77) and CXCL8 (6-77) synthetic analogue of MMP-8-cleaved CXCL8. (C)
Time course of air pouch PMN influx in response to CXCL8 (1-77) and CXCL8 (6-77) in Mmp8-/- mice (black) and wild type (white) mice as quantitated
by myeloperoxidase assay.
doi:10.1371/journal.pone.0000312.g007
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9,Glu
10. The
active site of murine and rat MMP-8 differs from that of human
MMP-8 by the presence of Lys
187 at S3’ instead of Ala
187 as found
in human MMP-8. Charge repulsion between Lys
187 in rodent
MMP-8 at S3’ with the P3’ Arg
12 in CXCL5 may preclude
CXCL5 cleavage at Arg
9,Glu
10 and instead favour cleavage at
Val
7,Leu
8. Here Glu
10 of CXCL5 would be the P3’ residue and
so likely forms a salt bridge with Lys
187. Although LIX shows
structural homology to CXCL5 and CXCL6 [52], MMP-8
exclusively cleaved CXCL5 and CXCL8 amongst all seven
human ELR
+ CXC chemokines. The activation of CXCL5 and
CXCL8 were shown by in vitro calcium flux and chemotaxis assays,
with the singular importance of MMP-8 in activating these human
chemokines in vivo shown from studies comparing the Mmp8-/-
mice with the wild type controls.
Our results reveal that chemokine processing is one of the most
important functions of MMP-8 in vivo and casts into doubt the
importance of MMP-8 in collagen degradation, a role that has
long been assumed to be of particular importance for PMN cell
migration and chemotaxis. Indeed, using air pouch models, no
difference in PMN cell migration and infiltration was observed in
response to synthetic analogues of the MMP-8 cleaved LIX,
CXCL8, and CXCL5. This shows that the PMN cell migration
machinery to chemotactic agents does not require MMP-8 activity
for responsiveness and that MMP-8 proteolysis of blood vessel
basement membrane and interstitial extracellular matrix compo-
nents is not essential for effective cell migration in vivo. Although
MMPs have traditionally been thought to cleave extracellular
matrix components and so disrupt extracellular matrix contacts
with the tumour and potentiate tumour cell spread and metastasis,
other biological roles for MMPs in cancer are now known [20,53].
Potentially related to this, sustained inflammatory responses
maintain a microenvironment advantageous to tumour growth
[54]. Indeed, MMP-8 modulates the innate immune response
induced by carcinogens leading to a protective role in preventing
tumour progression [34]. Mice lacking MMP-8 exhibited an
abnormal inflammatory response upon application of carcinogen,
with a delayed and more diffuse PMN influx to the site of the host
challenge. Once established though, the inflammatory response
was sustained and the mechanism for this is under investigation in
our laboratory. With MMP-8 being the first MMP reported to
have a protective role in tumorigenesis [34], the recognition of
further MMP anti-targets in cancer continues [35]. MMP-3 has
a protective role in squamous cell carcinoma [55] and macrophage
MMP-12 is an anti-target in lung carcinoma [56]. In these cases
the proteases were reported to alter leukocyte infiltration, although
the mechanism and substrates were not elucidated. In view of the
considerable number of chemokines now known to be processed
by MMPs, chemokines are strong candidate substrates to
phenotypically explain cancer anti-target activity in these MMP
genetic knockout mice.
The role of MMPs in LPS responsiveness and PMN migration
differs from that found for macrophages and CXCR4-displaying
leukocytes. Instead of promoting cell migration, MMP cleavage of
CC chemokines CCL2, -7, -8 and -13 results in the loss of agonist
activity and the generation of potent in vitro and in vivo CCR
antagonists [18,19]. Interestingly, the MMP-2 cleavage and
inactivation of CXCL12 [25] in the brain generates a potent
and selective neurotoxin implicated in HIV dementia [57,58]. We
also recently found that MMP-2 induces the shedding of the
integral plasma membrane chemokine CX3CL1 (fractalkine) by
release of the chemokine domain from the stalk at Ala
71,Leu
72
[23]. Further, the cell surface agonist activity of CX3CL1 was
converted to a soluble antagonist due to processing at Gly
4,Met
5.
Hence, MMPs dynamically regulate the biological activity of
chemokines and inflammatory and immune cell function in
pleiotropic ways. Our present studies suggest that an in cis feed-
forward activation mechanism occurs in which the PMN
integrates the tissue signalling milieu leading to controlled release
of MMP-8 that either directly or indirectly activates LIX in the
mouse, and CXCL8 and CXCL5 in man for further PMN
migration.
MATERIALS AND METHODS
Animals
Mice deficient in Mmp8 on a C57BL6/J6129 S background were
provided by Dr. S. Shapiro (Boston, USA). Wild type C57BL6/
J6129 S mice were purchased from the Jackson Laboratory.
Animal breeding and experimental procedures were approved by
the Animal Care Committee of the University of British
Columbia. 6–8 week old mice, segregated according to sex, were
used for all experiments.
In vivo PMN chemotaxis
The air pouch model of PMN chemotaxis was used as described
previously [59]. Sterile air (3 mL) was injected under the dorsal
skin of mice, two days later the air pouch was reinflated with 2 mL
of sterile air. On day five, 1 mg LPS (Sigma) in phosphate buffered
saline or 5 mg of chemokine in 1 mL 0.5% carboxymethylcellulose
was injected into the air pouch. After 0, 4, 8, or 12 h the mice
were sacrificed and air pouches lavaged with 2 mL of sterile PBS.
The resulting cell suspensions were lysed with 0.1% Triton-X100
and freeze-thawed. The PMN content was determined by
myeloperoxidase activity [60] using isolated PMN cells as
a standard. Cell lysate aliquots were separated by 7.5% SDS-
PAGE and MMP-8 was detected by western blot with 1:10,000
rabbit IgG against recombinant mouse MMP-8 [34].
Chemokines and proteinases
LIX (1-92), LIX (5-92), LIX (5-79), MIP-2, KC, DCIP-1, CXCL8,
CXCL8 (6-77), CXCL5 and CXCL5 (8-78) were chemically
synthesized and purified [61]. Recombinant human MMP-1, -2, -
8, -9, -13, -14, rodent MMP-8, -13, and recombinant human
MMP-8 hemopexin C-domain were expressed and purified
[18,19]. The synthetic hydroxamate MMP inhibitor Batimastat
(BB94) was from British Biotech (Oxford, UK).
Chemokine cleavage assays
Analysis of chemokine cleavage by MMPs was performed at
enzyme/chemokine ratios from 1:1000 up to 1:10 (w/w), at 37uC
in assay buffer (150 mM NaCl, 20 mM Tris, 5 mM CaCl2,
pH 7.5) in the presence of 1 mM APMA to activate proMMPs for
16–22 h. Digests were terminated by adding 5 mM EDTA.
Recombinant MMP-8 hemopexin C-domain, EDTA or BB94
were added to cleavage assays as indicated. Reaction products
were analyzed by 15% Tris-Tricine SDS-PAGE and stained with
Coomassie Brilliant Blue R250. The [M+H]
+/z of each cleavage
product was determined by matrix assisted laser desorption
ionization time of flight (MALDI-TOF) mass spectrometry on
a Voyager-DE
TM STR Biospectrometry Workstation (ABI). Mass
spectrometry data was deconvoluted to identify the substrate
cleavage sites and confirmed by Edman sequencing.
Heparin binding
To assess the effect of MMP truncations of LIX on heparin
binding, 0.5 mL of 4 mM chemokine in 10 mM potassium
LIX Processing by MMP-8
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TM heparin-
Sepharose column (GE Healthcare). Bound LIX and synthetic
analogues of MMP-cleaved LIX were eluted using a linear
gradient of 0 to 1.0 M NaCl over 20 min at a flow rate of 1.0 mL/
min and monitored by in-line absorbance at 215 nm.
Cells
Murine PMNs were isolated from bone marrow as previously
described [46] except PMNs were recovered from a density
gradient comprised of Histopaque 1077 layered on top of
Histopaque 1119 according to manufacture’s instructions (Sigma,
St Louis, USA). The murine pre-B 300-19 cell line stably
expressing human CXCR2 was supplied by Dr. B. Moser (Bern,
Switzerland). Cells were cultured in RPMI-1640 medium contain-
ing 10% fetal bovine serum, 1% glutamine and 5610
25 M b-
mercaptoethanol (Sigma) under puromycin (1.5 mg/mL) selection.
Measurement of intracellular calcium mobilization
Murine PMNs or CXCR2-transfected B300-19 cells (1610
7/mL
in RPMI-1640 media supplemented with 1% serum) were
incubated with 2 mM Fluo-4-acetoxymethyl ester (Molecular
Probes), for 30 min, 37uC. Cells were washed to remove
unincorporated agent and resuspended at 1610
6 cells/mL in
Hanks Balanced Salt Solution (Gibco), 20 mM HEPES, 2.5 mM
probenecid (Sigma). The cells were allowed to equilibrate at 37uC
for 5 min prior to addition of ligand as indicated. Calcium
concentration was monitored by excitation at 485 nm and
emission of 520 nm with a PerkinElmer LS50B spectrophotom-
eter. Calibration was performed by addition of 5 mM ionomycin
(Sigma) and 1 mM MnCl2 (Fisher Biotech).
In vitro chemotaxis assays
Murine PMNs or CXCR2-transfected murine pre-B cells were
plated (1610
6/well in aMEM, 0.1% BSA) in transwell inserts (pre-
coated with 10% fetal bovine serum) containing 3 mmo r8mm
pores respectively (Costar). Chemokines were added to the lower
chamber and the plates incubated at 37uC. PMN chemotaxis
assays were performed for 1 h. The migrated cells were then fixed
with 4% paraformaldehyde prior to counting. The murine pre-B
cell transfectants were assayed for 4 h after which the migrated
cells were counted.
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